Gothenburg, Sweden, October 20, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announces that the nomination committee ahead of the annual general meeting (AGM) 2027 has been appointed.
According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on May 22, 2024, the nomination committee shall, besides the Chair of the Board, consist of representatives of the three largest shareholders, or groups of shareholders, as of the last banking day in August 2026.
The three largest shareholders or groups of shareholders have now appointed their representatives, thus the nomination committee ahead of the AGM 2027 has the following members:
Daniel Johnsson has been appointed Chairman of the nomination committee.
The members of the nomination committee have been appointed by owners in IRLAB Therapeutics AB who represent a total of about 22 per cent of the total number of shares and votes in IRLAB Therapeutics AB as of the last banking day in August 2026.
Information about the nomination committee’s work and the instruction to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summon to the annual general meeting 2027 and on the company’s web page, www.irlab.se. The annual general meeting is planned to be held on June 3, 2027.
Shareholders who wish to submit proposals to the nomination committee shall do this in writing, no later than January 31, 2027, via e-mail ir@irlab.se.